ACIU News & Events

Reports Q1 revenue $1.12M, consensus $263,230. Andrea Pfeifer, CEO of AC Immune SA, commented: "The progress in our collaborations with Takeda and Eli Lilly reflect great confidence in our anti-Abeta active immunotherapy and Tau aggregation inhibitor small molecules, respectively. These have the potential to change the way we target the proteinopathies that drive Alzheimer's and other neurodegenerative diseases. This is further exemplified by the presentation of the interim results for ACI-7104 at AD/PD 2026 showing that our active immunotherapy targeting a-synuclein (a-syn) has the potential to modify disease pathology in Parkinson's disease. We also advanced our NLRP3 inhibitor ACI-19764 into clinical development, further demonstrating the power of AC Immune's technology to target the key pathways that contribute to neurodegeneration. We are now moving towards multiple value inflection points during 2026. These include Phase 2 data readouts on our active immunotherapies ACI-7104 and ACI-24, and initial results from the Phase 1 trial of ACI-19764 also anticipated this year."

AC Immune (ACIU) announced an agreement with Eli Lilly (LLY) to amend their 2018 license and collaboration agreement to research and develop Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. The amendment continues the research and collaboration to cover development of new lead Tau Morphomer candidates and potential back-up compounds. Under this amendment, AC Immune will receive a CHF 10M upfront payment and a subsequent milestone payment with Phase 1 dosing, in addition to milestones announced in a prior amendment. AC Immune is eligible for further development, regulatory and commercial milestones of over CHF1.7B, plus tiered percentage royalty payments in the low double digits, as previously disclosed.

AC Immune announced the presentation of Phase 1 data including the first in vivo images of TDP-43 pathology in the human brain, detected using its positron emission tomography - PET - tracer ACI-19626, at the International Conference on Alzheimer's and Parkinson's Disease. Initial data from the Phase 1 trial support ACI-19626's potential to detect pathological TDP-43 in the brains of patients with TDP-43 proteinopathies, enabling a precision medicine approach to multiple neurodegenerative diseases. Specifically, PET scans with ACI-19626 showed that tracer uptake was significantly higher in key regions of the brain in patients with frontotemporal dementia due to mutated C9orf72 than in the brains of healthy subjects. ACI-19626 showed good safety and tolerability, a dosimetry profile within accepted limits, and rapid brain uptake and washout, indicating a PK profile suitable for human brain imaging and potentially pharmacodynamic analysis of therapeutics targeting TDP-43 pathology. This potentially enables precision medicine across multiple neurodegenerative diseases.